Ординатура / Хирургия / Библиотека им академика М.И. Перельмана / Книга_5918_Библиотеки_им_академика_М_И_Перельмана

Polymeric nanocarriers (PNCs) are important and versatile in biotechnology, espe­cially in drug delivery. The short half-lives of many of these current treatments, along with the non-specic distribution and cytotoxicity of previously reported small-molecular drugs, have served as a main driving force in accelerating the development of polymeric DDSs (Kamaly etal. 2016). To date, we have observed the rst bench-to-bedside transformation of targeted and adaptable controlled release polymeric NPs for small-molecular drugs, from initial proof-of-concept invitro (Farokhzad etal. 2005) to successful invivo investigations (Gu etal. 2008), laying the groundwork for humans being tested and ongoing clinical trials in phase II for multiple cancer types (Hrkach et al. 2012). Because PNCs are typically between 10nm to 200nm in size, their biodistribution throughout the human body differs signicantly from that of tiny molecules. The drug’s distribution throughout the human body will be determined by the PNCs, greatly increasing the therapeutic impact. PNCs have an extremely large surface area to volume ratio, which favours surface conjugation for functional moieties. In terms of stability, reducing carrier size to the nanoscale can improve water penetration and consequently breakdown in the circumstances of biodegradable carriers. NPs tend to stay in solution without considerable sedimentation due to their low density and their unique combination of the electrostatic and van der Waals forces on the surface that are relevant at this size scale, prolonging their utility compared to bigger carriers (Kowalczuk etal. 2014). These nanoscale carriers, which are primarily made of biocompatible and biode­gradable polymers, provide several advantages that aid in therapeutic applications and biomedical research (Table7.2).